Can low estradiol, high SHBG, and inflammatory signaling reinforce one another?

The complex relationship between sex steroid bioactivity and systemic inflammation involves distinct feedback mechanisms, but the concept of a self-reinforcing cycle driven by high sex hormone-binding globulin (SHBG) is physiologically contradictory.

Endocrine-immune interactions

• Hormone availability: SHBG directly binds circulating estradiol and testosterone, reducing their free, biologically active fractions in tissue.
• Inflammatory pathway activation: Adequate estradiol levels suppress pro-inflammatory signaling by inhibiting NF-κB. Consequently, low estradiol levels remove this inhibition, promoting the release of cytokines like TNF-α, IL-1β, and IL-6.
• Altered receptor sensitivity: Inflammatory signaling can weaken tissue responsiveness by modifying hormone receptor expression and shifting receptor isoform ratios (such as ERα/ERβ), which alters downstream cellular sensitivity to endocrine signals.

The counter-regulatory role of SHBG

• Hepatic suppression: Chronic inflammatory states do not sustain high SHBG. Instead, pro-inflammatory cytokines (specifically TNF-α and IL-1β) directly suppress hepatic SHBG gene transcription and protein synthesis, leading to lower, rather than higher, SHBG levels.
• Anti-inflammatory signaling: In vitro evidence indicates that SHBG acts as an anti-inflammatory regulator, directly suppressing the expression of key inflammatory markers (MCP-1, TNF-α, and IL-6) in macrophages and adipocytes.

Bottom line

• While low estradiol promotes inflammatory signaling and inflammation alters hormone receptor sensitivity, the proposed self-reinforcing loop is biologically inconsistent because inflammatory cytokines suppress—rather than elevate—SHBG synthesis, while SHBG itself acts to counter inflammation.